These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2115513)

  • 1. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
    Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
    J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
    Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
    Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
    Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
    Ikenaka Y; Yajima K; Yahara H; Maruyama H; Matsumoto K; Okada K; Ueshima S; Matsuo O
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
    Bakker AH; Nieuwenbroek NM; Verheijen JH
    Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
    Nelles L; Lijnen HR; Collen D; Holmes WE
    J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.
    Larsen GR; Henson K; Blue Y
    J Biol Chem; 1988 Jan; 263(2):1023-9. PubMed ID: 3121618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
    Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
    Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
    Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
    J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
    J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator.
    Bakker AH; Rehberg EF; Marotti KR; Verheijen JH
    Protein Eng; 1995 Mar; 8(3):293-300. PubMed ID: 7479691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
    Lijnen HR; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1990 Aug; 64(1):61-8. PubMed ID: 2148848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
    Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
    Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
    Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
    Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.
    Berg DT; Burck PJ; Berg DH; Grinnell BW
    Blood; 1993 Mar; 81(5):1312-22. PubMed ID: 8382971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of aspartic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis.
    Weening-Verhoeff EJ; Quax PH; van Leeuwen RT; Rehberg EF; Marotti KR; Verheijen JH
    Protein Eng; 1990 Dec; 4(2):191-8. PubMed ID: 1963688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins.
    de Vries C; Veerman H; Blasi F; Pannekoek H
    Biochemistry; 1988 Apr; 27(7):2565-72. PubMed ID: 3132969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.